{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:53:40Z","timestamp":1791446020215,"version":"4.3.3"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test (MCT) can be used in selecting patients to receive MVC-containing combined antiretroviral therapy (cART). Using this MCT model, we assessed the effect of MVC on several HIV disease progression biomarkers during the MCT (MVC-specific effect) and following short-term (12-week) cART. We compared 45 patients on MVC monotherapy with a control group of 25 patients on MVC-sparing cART. We found that MVC did not modify any biomarkers in patients that had no virological response after the MCT. MVC-specific effects in patients with virological responses included increased CD8\n            <jats:sup>+<\/jats:sup>\n            T-cell activation and senescence levels, preservation of an increase in soluble CD14 (sCD14), and a decrease in D dimer levels. After 12 weeks, MVC-containing cART increased CD8\n            <jats:sup>+<\/jats:sup>\n            T-cell counts and preserved CD4\n            <jats:sup>+<\/jats:sup>\n            T-cell senescence levels compared with MVC-sparing cART. Moreover, there was a decrease in sCD14 levels in patients that received MVC-containing cART. In conclusion, effects compatible with CD8\n            <jats:sup>+<\/jats:sup>\n            T-cell redistribution in peripheral blood were observed after MVC therapy. However, MVC was associated with a favorable profile in HIV disease progression biomarkers only in patients with a virological response. These results support a potential clinical benefit of a therapy which includes MVC in HIV-infected patients.\n          <\/jats:p>","DOI":"10.1128\/aac.01406-12","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T06:53:01Z","timestamp":1346827981000},"page":"5858-5864","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Maraviroc on HIV Disease Progression-Related Biomarkers"],"prefix":"10.1128","volume":"56","author":[{"given":"M. Concepci\u00f3n","family":"Romero-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar","family":"Machmach","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Gonzalez-Serna","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Genebat","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildefonso","family":"Pulido","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"\u00c1lvarez-R\u00edos","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ferrando-Martinez","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"},{"name":"Laboratory of Molecular Immuno-Biology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[{"name":"Laboratory of Immunovirology, Biomedicine Institute of Seville, Service of Infectious Diseases, Virgen del Roc\u00edo University Hospital (IBiS\/CSIC\/SAS\/University of Seville), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/QAI.0b013e3181c5c83b","article-title":"CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2","volume":"54","author":"Asmuth DM","year":"2010","unstructured":"AsmuthDM. 2010. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J. Acquir. Immune Defic. Syndr. 54:394\u2013397.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.cdd.4400509","article-title":"Dynamic correlation of apoptosis and immune activation during treatment of HIV infection","volume":"6","author":"Badley AD","year":"1999","unstructured":"BadleyAD. 1999. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 6:420\u2013432.","journal-title":"Cell Death Differ."},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e3181f7f61a","article-title":"Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection","volume":"56","author":"Baker JV","year":"2011","unstructured":"BakerJV. 2011. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 56:36\u201343.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/infdis\/jir134","article-title":"Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death","volume":"203","author":"Boulware DR","year":"2011","unstructured":"BoulwareDR. 2011. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J. Infect. Dis. 203:1637\u20131646.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI5863","article-title":"Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues","volume":"103","author":"Bucy RP","year":"1999","unstructured":"BucyRP. 1999. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J. Clin. Invest. 103:1391\u20131398.","journal-title":"J. Clin. Invest."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181926c28"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.imlet.2009.10.001","article-title":"CD27 and CCR7 expression on naive T cells, are both necessary?","volume":"127","author":"Ferrando-Martinez S","year":"2010","unstructured":"Ferrando-MartinezS Ruiz-MateosE LealM. 2010. CD27 and CCR7 expression on naive T cells, are both necessary? Immunol. Lett. 127:157\u2013158.","journal-title":"Immunol. Lett."},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s100960050388","article-title":"Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy","volume":"18","author":"Franco JM","year":"1999","unstructured":"FrancoJM. 1999. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 18:733\u2013736.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013188"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkp293","article-title":"Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients","volume":"64","author":"Genebat M","year":"2009","unstructured":"GenebatM. 2009. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 64:845\u2013849.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/314660"},{"key":"e_1_3_3_14_2","first-page":"904","article-title":"Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up","volume":"6","author":"Giorgi JV","year":"1993","unstructured":"GiorgiJV. 1993. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J. Acquir. Immune Defic. Syndr. 6:904\u2013912.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027864"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.1.249"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050203"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","article-title":"Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression","volume":"16","author":"Liu Z","year":"1997","unstructured":"LiuZ. 1997. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16:83\u201392.","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/QAD.0b013e32834b3537","article-title":"Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment","volume":"25","author":"Palella FJ","year":"2011","unstructured":"PalellaFJJr. 2011. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25:1865\u20131876.","journal-title":"AIDS"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jinf.2011.12.017","article-title":"T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity","volume":"64","author":"Pulido I","year":"2012","unstructured":"PulidoI. 2012. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. J. Infect. 64:417\u2013423.","journal-title":"J. Infect."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ed18f6"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00753-11"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/598965"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq118"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1310\/hct1106-351","article-title":"The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients","volume":"11","author":"Wilkin TJ","year":"2010","unstructured":"WilkinTJ RibaudoHR TenorioAR GulickRM. 2010. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin. Trials 11:351\u2013358.","journal-title":"HIV Clin. Trials"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01406-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01406-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:03:09Z","timestamp":1645480989000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01406-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/AAC.01406-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01406-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"2012-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}